0.55
-0.0327(-5.63%)
Currency In USD
| Previous Close | 0.58 |
| Open | 0.57 |
| Day High | 0.7 |
| Day Low | 0.5 |
| 52-Week High | 1.92 |
| 52-Week Low | 0.49 |
| Volume | 5.01M |
| Average Volume | 283,915 |
| Market Cap | 11.7M |
| PE | -0.56 |
| EPS | -0.98 |
| Moving Average 50 Days | 0.56 |
| Moving Average 200 Days | 0.92 |
| Change | -0.03 |
If you invested $1000 in Longeveron Inc. (LGVN) since IPO date, it would be worth $7.4 as of February 26, 2026 at a share price of $0.549. Whereas If you bought $1000 worth of Longeveron Inc. (LGVN) shares 3 years ago, it would be worth $15.9 as of February 26, 2026 at a share price of $0.549.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell
GlobeNewswire Inc.
10 hours ago
Joshua Hare Joshua Hare, MD, FACC, FAHA, Co-Founder, Chief Science Officer and Executive Chairman, Longeveron MIAMI, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerativ
Longeveron® Appoints Stephen H. Willard as Chief Executive Officer
GlobeNewswire Inc.
Feb 13, 2026 9:30 PM GMT
Joshua Hare Joshua Hare, MD, FACC, FAHA, Co-Founder, Chief Science Officer and Executive Chairman, Longeveron Mr. Willard has a 30+ year track record of leadership across public and private sectors as CEO of multiple biotechnology and pharmaceuti
Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program
GlobeNewswire Inc.
Feb 05, 2026 2:15 PM GMT
Joshua Hare Joshua Hare, MD, FACC, FAHA, Co-Founder, Chief Science Officer and Executive Chairman, Longeveron The Mikaela Naylon Give Kids a Chance Act reauthorizes the Pediatric Priority Review Voucher (PPRV) Program and extends eligibility for